Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
The original version of this article unfortunately contained a mistake.
Main Authors: | Alice Tsai, Shu-Pei Wu, Eric Haseltine, Sanjeev Kumar, Samuel M. Moskowitz, Paul Panorchan, Kushal Shah |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-08-01
|
Series: | Pulmonary Therapy |
Online Access: | https://doi.org/10.1007/s41030-020-00128-3 |
Similar Items
-
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
by: Alice Tsai, et al.
Published: (2020-07-01) -
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
by: Mafalda Bacalhau, et al.
Published: (2023-03-01) -
Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
by: Lijia Zhang, et al.
Published: (2022-12-01) -
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
by: Burkhard Tümmler, et al.
Published: (2023-03-01) -
Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
by: Onofrio Laselva, et al.
Published: (2022-09-01)